Hematological Malignancies

Cardiovascular disease after therapy for HL: A detailed analysis of 9 collaborative EORTC-LYSA trials Cumulative incidence curves of first cardiovascular disease by LSQ-responder status and for the whole cohort (n=6,039)

LSQ responder

Total cohort

LSQ non responder

Maraldo et al, Lancet Hemat in press